Why the study?
Diabetes mellitus is a high risk factor in acute myocardial infarction, and this study aimed to determine the status of glycogen phosphorylase BB in AMI patients with and without diabetes.
GPBB is an early biomarker for acute myocardial infarction, but its levels are not significantly affected by the presence of diabetes mellitus.
GPBB may aid early AMI detection irrespective of diabetes; hypothesis-generating pending prospective validation.
Diabetes mellitus is associated with high risk factor in patients with acute myocardial infarction. In the myocardial infarction patients Glycogenphophorylse BB is a sensitive and specific marker.The present study was conducted with this objective to find out the status of GPBB in acute myocardial infarction with and without patients. For this study we included 64 AMI (33 with diabetes mellitus and 31 without diabetes mellitus) and 64 healthy subjects. AMI diagnosed according to the ACC guideline i.e. clinical symptom chest pain, electrocardiograph monitoring and elevated cardiac biomarker. Cardiac marker GPBB was elevated in all the patients within 1 hour after onset of chest pain but it was more elevated in AMI with diabetic patients as compare to the without diabetic patients and there is no statistically significant difference of GPBB between AMI with diabetic and without diabetic patients. We found the highest mean level of GPBB within 3 hour after onset of chest pain.
No takes yet. Share an insight, caveat, or question.
Chanchal Garg (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: